BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 26432963)

  • 1. Epigenetics application in the diagnosis and treatment of bladder cancer.
    Harb-de la Rosa A; Acker M; Kumar RA; Manoharan M
    Can J Urol; 2015 Oct; 22(5):7947-51. PubMed ID: 26432963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic Alterations in Bladder Cancer.
    Porten SP
    Curr Urol Rep; 2018 Oct; 19(12):102. PubMed ID: 30357502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global epigenetic profiling in bladder cancer.
    Dudziec E; Goepel JR; Catto JW
    Epigenomics; 2011 Feb; 3(1):35-45. PubMed ID: 22126151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine epigenomics: a promising path for bladder cancer diagnostics.
    Sánchez-Carbayo M
    Expert Rev Mol Diagn; 2012 Jun; 12(5):429-32. PubMed ID: 22702358
    [No Abstract]   [Full Text] [Related]  

  • 5. Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?
    Kim YJ; Kim WJ
    Investig Clin Urol; 2016 Jun; 57 Suppl 1(Suppl 1):S77-88. PubMed ID: 27326410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetics in prostate cancer: biologic and clinical relevance.
    Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
    Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of epigenetic interactions between miRNA and DNA methylation associated with gene expression as potential prognostic markers in bladder cancer.
    Shivakumar M; Lee Y; Bang L; Garg T; Sohn KA; Kim D
    BMC Med Genomics; 2017 May; 10(Suppl 1):30. PubMed ID: 28589857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and epigenetic biomarkers for early detection, therapeutic effectiveness and relapse monitoring in bladder cancer.
    Dumache R; David D; Kaycsa A; Minciu R; Negru S; Puiu M
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(1):163-7. PubMed ID: 21682190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic modifications in prostate cancer.
    Ngollo M; Dagdemir A; Karsli-Ceppioglu S; Judes G; Pajon A; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon DJ
    Epigenomics; 2014; 6(4):415-26. PubMed ID: 25333850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of epigenetics in kidney malignancies.
    la Rosa AH; Acker M; Swain S; Manoharan M
    Cent European J Urol; 2015; 68(2):157-64. PubMed ID: 26251734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Epigenetics of prostate cancer].
    Yi XM; Zhou WQ
    Zhonghua Nan Ke Xue; 2010 Jul; 16(7):635-41. PubMed ID: 20873600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moving forward in bladder cancer detection and diagnosis: the role of epigenetic biomarkers.
    Oliveira AI; Jerónimo C; Henrique R
    Expert Rev Mol Diagn; 2012 Nov; 12(8):871-8. PubMed ID: 23249204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetics in Health and Disease.
    Zhang L; Lu Q; Chang C
    Adv Exp Med Biol; 2020; 1253():3-55. PubMed ID: 32445090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic regulation and cancer (review).
    Chen QW; Zhu XY; Li YY; Meng ZQ
    Oncol Rep; 2014 Feb; 31(2):523-32. PubMed ID: 24337819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic epigenetic biomarkers in cancer.
    Costa-Pinheiro P; Montezuma D; Henrique R; Jerónimo C
    Epigenomics; 2015; 7(6):1003-15. PubMed ID: 26479312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feedback networks between microRNAs and epigenetic modifications in urological tumors.
    Liep J; Rabien A; Jung K
    Epigenetics; 2012 Apr; 7(4):315-25. PubMed ID: 22414795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetics in bladder cancer.
    Enokida H; Nakagawa M
    Int J Clin Oncol; 2008 Aug; 13(4):298-307. PubMed ID: 18704629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emodin modulates epigenetic modifications and suppresses bladder carcinoma cell growth.
    Cha TL; Chuang MJ; Tang SH; Wu ST; Sun KH; Chen TT; Sun GH; Chang SY; Yu CP; Ho JY; Liu SY; Huang SM; Yu DS
    Mol Carcinog; 2015 Mar; 54(3):167-77. PubMed ID: 24115089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of histone deacetylase inhibitors for bladder cancer treatment.
    Tanji N; Ozawa A; Kikugawa T; Miura N; Sasaki T; Azuma K; Yokoyama M
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):959-65. PubMed ID: 21707293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic biomarkers in urothelial bladder cancer.
    Kim WJ; Kim YJ
    Expert Rev Mol Diagn; 2009 Apr; 9(3):259-69. PubMed ID: 19379084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.